ENGN

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral, DNA-based gene therapies for cancer and other diseases. The company's proprietary defiNGene platform delivers therapeutic genes directly to target tissues using a transient delivery system. Their lead program focuses on treating bladder cancer through localized gene therapy administration. enGene is advancing multiple candidates through preclinical and clinical development stages.